H1N1 like vaccine coated nanopatch - Vaxxas

Drug Profile

H1N1 like vaccine coated nanopatch - Vaxxas

Alternative Names: A/California/7/2009-(H1N1)-like-vaccine-coated-nanopatch; H1N1-vaccine-nanopatch

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxxas
  • Developer University of Queensland; Vaxxas
  • Class Influenza A virus H1N1 vaccines; Vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H1N1 subtype

Most Recent Events

  • 01 Jul 2016 Phase-I clinical trials in Influenza-A virus H1N1 subtype (Prevention, In volunteers) in Australia (Transdermal) (ACTRN12616000880448)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top